Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 5/2017

01-05-2017 | Lymphomas (MR Smith, Section Editor)

Optimal Therapy for Early-Stage Hodgkin’s Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy

Authors: Andrea Riccardo Filippi, Mario Levis, Rahul Parikh, Bradford Hoppe

Published in: Current Oncology Reports | Issue 5/2017

Login to get access

Abstract

Purpose of Review

The aim of this article is to discuss the current role of radiotherapy (RT) for early-stage Hodgkin’s lymphoma (HL) in the context of risk-adapted and response-adapted treatment strategy, and describe changes in RT technical approach.

Recent Findings

In low-risk patients, RT could be omitted but, at the price of a lower progression-free survival, and its role is still debated. Ongoing trials are combining new agents with chemotherapy alone or response-adapted combined modality therapy, and results are awaited. Modern RT incorporates lower doses and smaller fields, together with the implementation of sophisticated delivery techniques aimed to reducing the dose to critical structures such as the heart.

Summary

The role of RT for early-stage HL is still under debate, and new combinations are emerging; an individualized approach should be recommended, considering all RT technical opportunities to minimize toxicity while maintaining efficacy.
Literature
1.
Pusey WA. Cases of sarcoma and Hodgkin’s disease treated by exposure to X-rays: a preliminary report. JAMA. 1902;XXXVIII(3):166–9.CrossRef
2.
Gilbert R. Radiotherapy in Hodgkin’s disease (malignant granulomatosis): anatomic and clinical foundations; governing principles; results. Nucl Med. 1939;41(2):198–241.
3.
Peters MV. A study of survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol Radium Therapy, Nucl Med. 1950;63(3):299–311.
4.
Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601–8.CrossRefPubMed
5.
Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–206.CrossRefPubMed
6.
Borchmann S, von Treskow B, Engert A. Current developments in the treatment of early stage classical Hodgkin lymphoma. Curr Opin Oncol. 2016;28:377–83.CrossRefPubMed
7.
Engert A, Raemaekers J. Tretament of early stage Hodgkin lymphoma. Semin Hematol. 2016;53(3):165–70.CrossRefPubMed
8.
Parikh RR, Groosbard ML, Harrison LB, Yahalom J. Early-stage classic Hodgkin lymphoma: the utilization of radiation therapy and its impact on overall survival. Int J Radiat Oncol Biol Phys. 2015;93(3):684–93.CrossRefPubMed
9.
Specht L, Yahalom J. The concept and evolution of involved site radiotherapy for lymphoma. Int J Clin Oncol. 2015;20(5):849–54.CrossRefPubMed
10.
Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]Fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.CrossRefPubMed
11.
Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79(3):270–7.CrossRefPubMed
12.
•• Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12):1188–94. One of the most important steps towards response-adapted therapy and new radiotherapy concepts (INRT). CrossRefPubMed
13.
Raemaekers JMM. Early FDG-PET adapted treatment improves the outcome of early FDG-PET-positive patients with stages I/II Hodgkin lymphoma (HL): final results of the randomized intergroup EORTC/LYSA/FIL H10 trial. 2015; Palazzo dei Congressi, Lugano (Switzerland), 17–20 June 2015: 13th International Conference on Malignant Lymphoma.
14.
•• Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–607. One of the most important steps towards response-adapted therapy. CrossRefPubMed
15.
Filippi AR, Botticella A, Bellò M, et al. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin’s lymphoma treated with combined modality therapy. Leuk Lymph. 2013;54(6):1183–7.CrossRef
16.
Simontacchi G, Filippi AR, Ciammella P, et al. Interim PET after two ABVD cycles in early-stage Hodgkin lymphoma: outcomes following the continuation of chemotherapy plus radiotherapy. Int J Radiat Oncol Biol Phys. 2015;92(5):1077–83.CrossRefPubMed
17.
Abramson JS, Arnason JE, LaCasce AS, et al. Brentuximab vedotin plus AVD for non-bulky limited stage classical Hodgkin lymphoma: a phase 2 trial. J Clin Oncol. 2015;33(Suppl 15):8505.
18.
Kumar A, Yahalom J, Schoder H, et al. Preliminary efficacy and safety of brentuximab vedotin and AVD chemotherapy followed by involved-site radiotherapy in early stage, unfavourable risk Hodgkin lymphoma. Hemotol Oncol. 2015;33(Suppl):100–80.
19.
Federico M, Luminari S, Pellegrini C, et al. Brentuximab vedotin followed by ABVD+/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. Haematologica. 2016;101:e139–41.CrossRefPubMedPubMedCentral
20.
21.
Brentuximab vedotin combined with AVD chemotherapy and involved-site radiotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma. ClinicalTrials.​gov Identifier: NCT01868451.
22.
Brentuximab vedotin as consolidation treatment in patients with stage I/II HL and PET positivity after 2 cycles of ABVD. ClinicalTrials.​gov Identifier: NCT02298283.
23.
Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148:890–7.CrossRefPubMedPubMedCentral
24.
Poen JC, Hoppe RT, Horning SJ. High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Phys. 1996;36:3–12.CrossRefPubMed
25.
Wendland MM, Asch JD, Pulsipher MA, et al. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoetic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin’s disease. Am J Clin Oncol. 2006;29:189–95.CrossRefPubMed
26.
Kahn S, Flowers C, Xu Z, Esiashvili N. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma? Int J Radiat Oncol Biol Phys. 2011;81(1):175–80.CrossRefPubMed
27.
Eroglu C, Kaynar L, Orhan O, et al. Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Am J Clin Oncol. 2015;38:68–73.CrossRefPubMed
28.
Levis M, Piva C, Filippi AR, et al. Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin’s lymphoma with incomplete response before autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2016; doi:10.​2016/​j.​clml.​2016.​09.​008.PubMed
29.
Goda JS, Massey C, Kuruvilla J, et al. Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous stem cell transplant. Int J Radiat Oncol Biol Phys. 2012;84(3):e329–35.CrossRefPubMed
30.
Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853–62.CrossRefPubMed
31.
Moskowitz AJ, Schoder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16:284–92.CrossRefPubMed
32.
Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–9.CrossRefPubMed
33.
Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–41.CrossRef
34.
•• van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34:235–43. Probably the most important study on dose-response relationship for the heart in HL. CrossRefPubMed
35.
•• Schaapveld M, Aleman BMP, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;373(26):2499–511. One of the most relevant studies on secondary malignancies in HL with long-term follow-up. CrossRefPubMed
36.
Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol. 2002;13(supplement 1):79–83.CrossRefPubMed
37.
Ricardi U, Filippi AR, Piva C, Franco P. The evolving role of radiotherapy in early stage Hodgkin lymphoma. Med J Haematol Infect Dis. 2014;6(1):e2014035.CrossRef
38.
•• Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–62. New definition of radiation volumes for early-stage HL. CrossRefPubMed
39.
Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol. 2008;26:5170–4.CrossRefPubMed
40.
Paumier A, Ghalibafian M, Beaudre A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2011;80(1):199–205.CrossRefPubMed
41.
Maraldo MV, Aznar MC, Vogelius IR, et al. Involved node radiation therapy: an effective alternative in early-stage Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2013;85(4):1057–65.CrossRefPubMed
42.
• Filippi AR, Ciammella P, Piva C, et al. Involved-site image-guided intensity-modulated radiotherapy vs. 3D conformal radiotherapy in supra-diaphragmatic early stage Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2014;89(2):370–5. Early evidence in favor of a limited field/high techcnology RT approach for early-stage HL. CrossRefPubMed
43.
Goodman KA, Toner S, Hunt M, et al. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys. 2005;62(1):198–206.CrossRefPubMed
44.
Weber DC, Peguret N, Dipasquale G, Cozzi L. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys. 2009;75:1578–86.CrossRefPubMed
45.
Paumier A, Ghalibafian M, Gilmore J, et al. Dosimetric benefits of intensity modulated radiotherapy combined with deep inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2011;82(4):1522–7.CrossRefPubMed
46.
Campbell BA, Hornby C, Cunninghame J. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol. 2012;23(5):1259–66.CrossRefPubMed
47.
Koeck J, Abo-Madyan Y, Lohr, et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to German Hodgkin Study Group (GHSG): the roles of intensity modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(1):268–76.CrossRefPubMed
48.
49.
Maraldo MV, Dabaja BS, Filippi AR, et al. Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):144–52.CrossRefPubMed
50.
Filippi AR, Ragona R, Piva C, et al. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk. Int J Radiat Oncol Biol Phys. 2015;92(1):161–8.CrossRefPubMed
51.
Voong KR, McSpadden K, Pinnix CC, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol. 2014;9:94.CrossRefPubMedPubMedCentral
52.
• Parikh RR, Grossbard ML, Harrison LB, Yahalom. Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma. Radiother Oncol. 2016;118(1):52–9. Early evidence in favor of IMRT for early-stage HL. CrossRefPubMed
53.
Petersen PM, Aznar MC, Berthelsen AK, et al. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol. 2015;54(1):60–6.CrossRefPubMed
54.
Aznar MC, Maraldo MV, Schut DA, et al. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both? Int J Radiat Oncol Biol Phys. 2015;92(1):169–74.CrossRefPubMed
55.
Maraldo MV, Brodin P, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early stage mediastinal Hodgkin’s lymphoma. Ann Oncol. 2013;24(8):2113–8.CrossRefPubMed
56.
Weber DC, Johanson S, Peguret N, et al. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage Hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys. 2011;81(2):490–7.CrossRefPubMed
57.
Cella L, Conson M, Pressello MC, et al. Hodgkin’s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms. Radiat Oncol. 2013;8:22.CrossRefPubMedPubMedCentral
58.
Filippi AR, Ragona R, Fusella M, et al. Changes in breast cancer risk associated with different volumes, doses, and techniques in female Hodgkin lymphoma patients treated with supra-diaphragmatic radiation therapy. Practical Rad Onc. 2013;3(3):216–22.CrossRef
59.
Li J, Dabaja B, Reed V, et al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys. 2011;81(1):167–74.CrossRefPubMed
60.
Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;84(2):449–55.CrossRefPubMed
61.
Chera BS, Rodriguez C, Morris CG, Louis D, Yeung D, Li Z, Mendenhall NP. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin’s lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(4):1173–80.CrossRefPubMed
62.
Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. Incidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys. 2013;87(1):46–52.CrossRefPubMed
63.
Zeng C, Plastaras JP, James P, et al. Proton pencil beam scanning for mediastinal lymphoma: treatment planning and robustness assessment. Acta Oncol. 2016;55(9–10):1132–8.CrossRefPubMed
64.
Wray J, Flampouri S, Slayton W, et al. Proton therapy for pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2016;63(9):1522–6.CrossRefPubMed
65.
Hoppe BS, Flampouri S, Su Z, et al. Consolidative involved-node proton therapy for stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys. 2012;83(1):260–7.CrossRefPubMed
66.
•• Hoppe BS, Tsai H, Larson G, et al. Proton therapy patterns-of-care and early outcomes for Hodgkin lymphoma: results from the Proton Collaborative Group Registry. Acta Oncol. 2016;55(11):1378–80. Early evidence in favor of PT for early-stage HL. CrossRefPubMed
67.
Metadata
Title
Optimal Therapy for Early-Stage Hodgkin’s Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy
Authors
Andrea Riccardo Filippi
Mario Levis
Rahul Parikh
Bradford Hoppe
Publication date
01-05-2017
Publisher
Springer US
Published in
Current Oncology Reports / Issue 5/2017
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-017-0592-7

Other articles of this Issue 5/2017

Current Oncology Reports 5/2017 Go to the issue

Gastrointestinal Cancers (J Meyer, Section Editor)

Immunotherapy for Esophageal Squamous Cell Carcinoma

Leukemia (A Aguayo, Section Editor)

Philadelphia-Like Acute Lymphoblastic Leukemia in Adults

Breast Cancer (B Overmoyer, Section Editor)

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Emerging Variants of Castration-Resistant Prostate Cancer

Melanoma (RJ Sullivan, Section Editor)

Adjuvant Therapy for Melanoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits